Cancer Policy First ODAC meeting since Trump’s inauguration scheduled for May 20-21 May 09, 2025Vol.51 No.18By Jacquelyn Cobb
Drugs & Targets FDA grants accelerated approval to avutometinib + defactinib for KRAS-mutated recurrent LGSOC May 09, 2025Vol.51 No.18
Clinical Roundup Sotorasib + panitumumab offers better outcomes in colorectal cancer that no longer responds to treatment May 02, 2025Vol.51 No.17
Regulatory News Makary vows to speed up drug approvals and end FDA’s “cozy” relationship with industryCommissioner promises to protect scientific integrity while bringing in “fresh” MAHA ideas April 25, 2025Vol.51 No.16By Claire Marie Porter
Cancer Policy ASCO seeks to engage new leaders of NIH, CMS, and FDA April 25, 2025Vol.51 No.16By Jacquelyn Cobb
In Brief FDA’s Richard Pazdur to receive the 2025 AACR Enduring Impact Award for transformative service to cancer science and medicine April 25, 2025Vol.51 No.16
Drugs & Targets FDA approves penpulimab-kcqx for non-keratinizing nasopharyngeal carcinoma April 25, 2025Vol.51 No.16
Drugs & Targets FDA grants Breakthrough Therapy designation for B7-H3 CAR T-cell therapy for diffuse intrinsic pontine glioma April 25, 2025Vol.51 No.16
Regulatory News RFK Jr. urges FDA staff to resist “agency capture” by special interests and resist “deep state”Whistleblowers will be “honored” April 18, 2025Vol.51 No.15By Jacquelyn Cobb
Drugs & Targets FDA approves nivolumab + ipilimumab for unresectable or metastatic HCC April 18, 2025Vol.51 No.15
